Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2020-10-20 Board/Management Inform…
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Valberedning utsedd inför årsstämman 2021
Board/Management Information Classification · 99% confidence The document is a press release dated 2020-10-20 announcing the composition of the Nomination Committee (Valberedning) for the upcoming Annual General Meeting (årsstämman) in 2021. This relates directly to the governance and preparation for the AGM, specifically concerning the nomination of board members and committee members. While it is related to the AGM, it is not the AGM presentation itself (AGM-R) or the proxy materials (DEF 14A/PSI). It is an announcement concerning the governance structure leading up to the meeting. Given the options, this type of announcement regarding board/governance structure leading up to a shareholder meeting fits best under Governance Information (CGR) or potentially as a general Regulatory Filing (RNS). Since it specifically details the composition of the committee responsible for nominations, which is a core governance function, CGR is the most precise fit among the specific codes, although it is a very short announcement. If the document were a full report on governance practices, CGR would be certain. As it is a specific announcement about a governance body (Nomination Committee), CGR is chosen over the general RNS, as it is more specific than a general regulatory filing.
2020-10-20 Swedish
Nomination Committee appointed ahead of 2021 Annual General Meeting
Regulatory Filings Classification · 99% confidence The document is a press release from Cantargia AB dated October 20, 2020, announcing the appointment of the Nomination Committee ahead of the 2021 Annual General Meeting (AGM). While it mentions the AGM, the core content is about the composition and responsibility of the Nomination Committee, which is a key component of corporate governance related to board composition and shareholder meetings. This aligns most closely with 'Board/Management Information' (MANG) or potentially 'Governance Information' (CGR). However, since the announcement specifically concerns the committee responsible for nominating directors for the upcoming AGM, and it details the composition of this committee, it is a specific announcement related to the governance structure leading up to the AGM. Given the options, MANG covers changes/appointments related to the board/management structure, which the Nomination Committee directly influences. It is not the AGM presentation itself (AGM-R), nor is it a general governance report (CGR). It is a specific announcement about a body related to board appointments.
2020-10-20 English
Extraordinary general meeting in Cantargia AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled 'Extraordinary general meeting in Cantargia AB (publ)' and details resolutions passed at this meeting, specifically concerning the election of a new board member, remuneration for that member, and the issuance of warrants related to an employee option program. These actions (board changes, remuneration decisions, and shareholder votes on capital structure changes) are core components of a General Meeting. Since the document reports the *results* of the vote/meeting, it aligns best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the Annual General Meeting (or, by extension, Extraordinary General Meetings, as the content is directly related to meeting outcomes). While board changes (MANG) and capital changes (SHA) are mentioned, the context is the resolution passed *at the meeting* itself.
2020-10-13 English
Extra bolagsstämma i Cantargia AB (publ)
AGM Information Classification · 99% confidence The document is titled "Extra bolagsstämma i Cantargia AB (publ)" which translates to "Extra General Meeting in Cantargia AB (publ)". The content details resolutions passed at this meeting, specifically electing a new board member (Flavia Borellini), setting her remuneration, and approving the issuance of warrants related to an employee option program. These actions—resolutions passed at a general meeting and related board/compensation changes—are core components of shareholder/governance meetings. Since the document reports the *results* of the vote and decisions made, it aligns best with the general scope of shareholder meeting materials. While 'AGM-R' is for Annual General Meetings, this is an 'Extra' (Extraordinary) General Meeting. Given the options, 'AGM-R' is the closest fit for reporting decisions made at a shareholder meeting, although 'DEF 14A' (Remuneration) or 'MANG' (Board changes) are partially relevant, the primary context is the meeting resolution itself. However, the specific category 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is defined as 'Official results from shareholder votes at any general meeting (AGM or EGM)'. This document explicitly details the resolutions passed at an EGM (Extraordinary General Meeting). Therefore, DVA is the most precise classification.
2020-10-13 Swedish
Cantargia slutför rekryteringen och rapporterar en positiv interims-uppdatering av kombinationsstudien med CAN04 i bukspottkörtelcancer
Earnings Release Classification · 99% confidence The document is titled "Pressmeddelande" (Press Release) and dated October 8, 2020. It announces the completion of patient recruitment and reports positive interim updates from a clinical study (CANFOUR) involving the drug CAN04 for pancreatic cancer. It details preliminary efficacy data (response rates) and safety observations. The final paragraph explicitly states: "Denna information är sådan som Cantargia AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is such information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation). This structure—a formal announcement of material, non-public information required by market regulations—is characteristic of a general regulatory announcement, often categorized as a Regulatory Filing (RNS) when it doesn't fit a more specific financial report type (like 10-K, ER, or IR). It is not a full financial report (10-K or IR), an earnings release (ER) focusing only on key figures, or a management discussion (MDA). It is a specific operational/clinical update released via regulatory channels. FY 2020
2020-10-08 Swedish
Cantargia completes recruitment and reports positive interim update in CAN04 pancreatic cancer combination therapy
Regulatory Filings Classification · 99% confidence The document is explicitly labeled as a "Press release" and announces clinical trial updates, including recruitment completion and positive interim data regarding efficacy and side effects for the CAN04 drug in pancreatic cancer patients. It provides key financial/operational highlights (response rates, side effects) but is not a comprehensive annual report (10-K), a detailed interim report (IR), or a full transcript (CT). This format, announcing key results outside of a mandatory periodic filing structure, strongly aligns with an Earnings Release (ER), which typically covers periodical financial or operational results highlights. Although it discusses clinical data rather than pure financials, in the context of biotech/pharma, these operational updates often serve the same function as an ER for investors. It is too detailed for a simple RPA and does not fit any other specific category.
2020-10-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.